News & Updates
Filter by Specialty:
Belzutifan 120 mg on par with higher dose in advanced clear cell RCC
Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.
Belzutifan 120 mg on par with higher dose in advanced clear cell RCC
13 Dec 2024
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
Ribociclib plus radiotherapy feasible in metastatic breast cancer
The addition of CDK4/6 inhibitor ribociclib to palliative radiotherapy is relatively safe in patients with metastatic breast cancer, reports a study.
Ribociclib plus radiotherapy feasible in metastatic breast cancer
13 Dec 2024
OLE data FORTIFY risankizumab role in Crohn’s disease
Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
